Most developed countries apply some form of IRP as a factor in negotiating or regulating domestic pricing. With the emergence of risk sharing agreements and in particular confidential price / volume agreements tied to HTA assessments some experts are suggesting the end of IRP systems in imminent. In contrast, some countries like Canada are placing greater reliance on IRP to lower drug prices.
Founder & Senior Consultant
PDCI Market Access
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of NextLevel Life Sciences.